Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Prepares For Diovan Patent Expiries; Looks To New Product Launches

Executive Summary

Novartis is shifting its marketing muscle away from the mega-drug Diovan and encouraging new hypertensive patients to take Tekturna or Exforge in hopes of forestalling generic competition that will begin to surface in two years, according to Joe Jimenez, who heads the pharmaceuticals business

You may also be interested in...



Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO

The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions

Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO

The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions

Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol

FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel